MedTrace Logo

A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

NCT04494243 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-07-21

No results posted yet for this study

Summary

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in healthy volunteers.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

AD-214 10/600mg

1 tablet administered before the breakfast during 7 days

DRUG

Rabeprazole 10mg

1 tablet administered before the breakfast during 7 days

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Seunghwan Lee, M.D.,Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2021-01-15
Completion
2021-01-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04494243 on ClinicalTrials.gov